Dr. Hamlin on Key Points of a Study on Cerdulatinib in Non-Hodgkin Lymphoma

Paul A. Hamlin, MD
Published: Monday, Nov 06, 2017



Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a phase II study investigating cerdulatinib in patients with non-Hodgkin lymphoma.

There is an increasing amount of oral agents that will be available for patients with a good safety margin and the possibility of combinations, states Hamlin.

According to Hamlin, we are entering an era where the understanding of biology will allow us to address the patients
SELECTED
LANGUAGE


Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a phase II study investigating cerdulatinib in patients with non-Hodgkin lymphoma.

There is an increasing amount of oral agents that will be available for patients with a good safety margin and the possibility of combinations, states Hamlin.

According to Hamlin, we are entering an era where the understanding of biology will allow us to address the patients



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x